


AMENDMENTS TO THE SPECIFICATION

Please delete the present Abstract of the Disclosure.

Please add the following new Abstract of the Disclosure:

There are provided a uracil derivative represented by the general formula (I):



or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for the treatment of, in particular, allergic diseases in which a type IV allergic reaction participates, which comprises the above-mentioned uracil derivative or pharmaceutically acceptable salt thereof as an active ingredient, that is, there are provided a novel compound useful for treating various allergic diseases, in particular, diseases in which a type IV allergic reaction participates, and a pharmaceutical composition for the treatment of allergic diseases comprising this compound as an active ingredient.